Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review

por Maur, Michela, Omarini, Claudia, Piacentini, Federico, Fontana, Annalisa, Pettorelli, Elisa, Cascinu, Stefano
Publicado 2017

Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma

por Maur, Michela, Toss, Angela, Dominici, Massimo, Frassoldati, Antonio, Corradini, Paolo, Maiorana, Antonio, Fontana, Annalisa, Conte, Pierfranco
Publicado 2015

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!

por Omarini, Claudia, Maur, Michela, Luppi, Gabriele, Narni, Franco, Luppi, Mario, Dominici, Massimo, Longo, Giuseppe, Piacentini, Federico
Publicado 2020

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations

por Guaitoli, Giorgia, Bertolini, Federica, Bettelli, Stefania, Manfredini, Samantha, Maur, Michela, Trudu, Lucia, Aramini, Beatrice, Masciale, Valentina, Grisendi, Giulia, Dominici, Massimo, Barbieri, Fausto
Publicado 2021

Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence

por Aramini, Beatrice, Masciale, Valentina, Grisendi, Giulia, Bertolini, Federica, Maur, Michela, Guaitoli, Giorgia, Chrystel, Isca, Morandi, Uliano, Stella, Franco, Dominici, Massimo, Haider, Khawaja Husnain
Publicado 2022

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature

por Isca, Chrystel, Piacentini, Federico, Mastrolia, Ilenia, Masciale, Valentina, Caggia, Federica, Toss, Angela, Piombino, Claudia, Moscetti, Luca, Barbolini, Monica, Maur, Michela, Dominici, Massimo, Omarini, Claudia
Publicado 2021

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer

por Agarwal, Neeraj, Machiels, Jean-Pascal, Suárez, Cristina, Lewis, Nancy, Higgins, Michaela, Wisinski, Kari, Awada, Ahmad, Maur, Michela, Stein, Mark, Hwang, Andy, Mosher, Rebecca, Wasserman, Ernesto, Wu, Gang, Zhang, Hefei, Zieba, Renata, Elmeliegy, Mohamed
Publicado 2016

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme

por Altomonte, Maresa, Di Giacomo, Anna Maria, Queirolo, Paola, Ascierto, Paolo Antonio, Spagnolo, Francesco, Bajetta, Emilio, Calabrò, Luana, Danielli, Riccardo, de Rosa, Francesco, Maur, Michela, Chiarion-Sileni, Vanna, Ferrucci, Pier Francesco, Giannarelli, Diana, Testori, Alessandro, Ridolfi, Ruggero, Maio, Michele
Publicado 2013

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

por Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Michela, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri, Valter
Publicado 2018

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

por Schöffski, Patrick, Tan, Daniel S W, Martín, Miguel, Ochoa-de-Olza, María, Sarantopoulos, John, Carvajal, Richard D, Kyi, Chrisann, Esaki, Taito, Prawira, Amy, Akerley, Wallace, De Braud, Filippo, Hui, Rina, Zhang, Tian, Soo, Ross A, Maur, Michela, Weickhardt, Andrew, Krauss, Jürgen, Deschler-Baier, Barbara, Lau, Allen, Samant, Tanay S, Longmire, Tyler, Chowdhury, Niladri Roy, Sabatos-Peyton, Catherine A, Patel, Nidhi, Ramesh, Radha, Hu, Tiancen, Carion, Ana, Gusenleitner, Daniel, Yerramilli-Rao, Padmaja, Askoxylakis, Vasileios, Kwak, Eunice L, Hong, David S
Publicado 2022

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

por Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Ancona, Cristina, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Antonio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri on behalf of The EVA Study Group, Valter
Publicado 2018

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

por Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri on behalf of The EVA Study Group, Valter
Publicado 2018

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

por Chan, Stephen L., Schuler, Martin, Kang, Yoon-Koo, Yen, Chia-Jui, Edeline, Julien, Choo, Su Pin, Lin, Chia-Chi, Okusaka, Takuji, Weiss, Karl-Heinz, Macarulla, Teresa, Cattan, Stéphane, Blanc, Jean-Frederic, Lee, Kyung-Hun, Maur, Michela, Pant, Shubham, Kudo, Masatoshi, Assenat, Eric, Zhu, Andrew X., Yau, Thomas, Lim, Ho Yeong, Bruix, Jordi, Geier, Andreas, Guillén-Ponce, Carmen, Fasolo, Angelica, Finn, Richard S., Fan, Jia, Vogel, Arndt, Qin, Shukui, Riester, Markus, Katsanou, Vasiliki, Chaudhari, Monica, Kakizume, Tomoyuki, Gu, Yi, Porta, Diana Graus, Myers, Andrea, Delord, Jean-Pierre
Publicado 2022